A bovine infectious rhinotracheitis virus suspension culture live vaccine and a preparation method thereof
By limiting the inoculation window, maintaining feeding after inoculation, controlling metabolic indicators, using low-shear clarification, and employing a composite freeze-drying protection system, the batch-to-batch variability and storage stability issues of bovine infectious rhinotracheitis virus suspension culture live vaccine were resolved, achieving efficient virus titer maintenance and freeze-drying survival rate.
Patent Information
- Application Number
- CN202610764999.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-05-29
- Publication Date
- 2026-11-13
AI Technical Summary
The industrial production of live vaccines using bovine infectious rhinotracheitis virus suspension culture currently faces several challenges, including significant batch-to-batch variations in virus proliferation, unstable determination of harvest endpoints, substantial titer loss during freeze-drying and reconstitution, and insufficient stability during long-term storage at 2-8°C.
By limiting the inoculation window, maintaining feeding after inoculation, controlling metabolic indicators, low-shear harvesting clarification, and a composite freeze-drying protection system, combined with MDBK suspension cell culture, freeze-dried formulations were prepared, including a freeze-drying protection system of trehalose, sucrose, hydrolyzed gelatin, skim milk powder, monosodium glutamate, hydroxyethyl starch, and betaine, and then subjected to low-temperature low-shear mixing and two-stage freeze-drying.
It improved the batch-to-batch consistency of virus harvest titer, freeze-drying survival rate, and stability during storage at 2-8℃, ensuring the retention rate of virus titer and the effectiveness of the vaccine.
Smart Images

Figure SMS_1
Abstract
Description
Technical Field
[0001] This invention belongs to the field of animal vaccines and veterinary biological products technology, specifically relating to a live vaccine for bovine infectious rhinotracheitis virus suspension culture and its preparation method. Background Technology
[0002] Infectious bovine rhinotracheitis (IBR), also known as red nose disease, is an acute, febrile, and contagious disease caused by bovine herpesvirus type 1 (BHV-1). Infected cattle may exhibit symptoms such as fever, lethargy, loss of appetite, increased nasal discharge, conjunctivitis, respiratory symptoms, and reproductive disorders. The virus can remain dormant in nerve ganglia and other sites after infection, and can be reactivated under stress or when immunity is weakened. Therefore, once an infection occurs in large-scale cattle farms, they often face the pressure of long-term viral carriage, recurrent outbreaks, and continuous transmission.
[0003] With the increasing intensification of cattle farming, the proportion of off-site fattening, and large-scale breeding in my country, the economic losses caused by infectious bovine rhinotracheitis to beef and dairy cattle production are gradually becoming more severe. Vaccination is an important means to reduce morbidity, reduce antibiotic use, and stabilize the health of cattle herds. Attenuated live vaccines can induce good immune protection with relatively low antigen doses, but their industrial preparation process is quite sensitive to cell state, virus inoculation window, culture metabolic environment, harvest endpoint, freeze-drying protection system, and cold chain storage conditions.
[0004] Existing technologies have disclosed that the Bovine Infectious Rhinotracheitis Virus (BIV) JSM strain can be cultured in MDBK cells, and have also disclosed conventional MDBK suspension culture, fixed-time harvesting, and gelatin-sucrose-based protectants. However, in the industrial production of single-vaccine strains, relying solely on conventional cell density, MOI, temperature, pH, and dissolved oxygen parameters is still insufficient to fully address the following issues: First, when cells are in a state of rapid proliferation or high metabolic load before inoculation, the viral proliferation level fluctuates significantly between batches; second, nutrient consumption and lactic acid accumulation in the cell culture medium after inoculation affect the persistence of viral replication, and fixed-time harvesting can easily result in insufficient titers in early harvesting or viral attenuation in late harvesting; third, the virus is susceptible to mechanical shearing, foaming, and temperature fluctuations during harvesting, clarification, mixing, and freeze-drying, leading to a loss of effective viral titers; fourth, traditional protection systems do not adequately support the maintenance of live virus particle structure and titers after reconstitution under long-term storage conditions at 2-8℃.
[0005] Therefore, it is necessary to provide a complete technical solution based on MDBK suspension culture, which simultaneously defines the inoculation window, maintains post-inoculation feeding, controls metabolic indicators, performs low-shear harvest clarification, low-temperature low-shear aseptic mixing, and a composite freeze-drying protection system, thereby improving the harvest titer, batch-to-batch consistency, freeze-drying survival rate, and storage stability of bovine infectious rhinotracheitis virus suspension culture live vaccine. Summary of the Invention
[0006] The purpose of this invention is to provide a live vaccine for bovine infectious rhinotracheitis virus suspension culture and its preparation method, in order to solve the problems of large batch-to-batch differences in virus proliferation, unstable determination of harvest endpoint, large titer loss during freeze-drying and reconstitution processes, and insufficient stability during long-term storage at 2-8℃ in the existing industrial preparation of live vaccines.
[0007] To achieve the above objectives, this invention provides a live vaccine for bovine infectious rhinotracheitis virus (BRV) suspension culture. The live vaccine is a freeze-dried preparation containing attenuated BRV antigen and a freeze-drying protection system. The attenuated BRV antigen is obtained by culturing MDBK suspension cells through a proliferation phase and a post-inoculation feeding maintenance phase.
[0008] In a preferred embodiment, the MDBK suspension cell density before inoculation is 2.8×10^6-4.5×10^6 cells / ml, with a cell viability of not less than 92%, and the pH fluctuation not exceeding 0.15 and dissolved oxygen fluctuation not exceeding 10% within 6 hours before inoculation. A weakened strain of bovine infectious rhinotracheitis virus is inoculated with an MOI of 0.005-0.03. 6-10 hours after inoculation, 10%-35% (v / v) of supplemental feeding medium is added, and the glucose concentration in the culture medium is controlled at 1.0-3.0 g / L, and the lactate concentration not exceeding 3.0 g / L. The virus fluid is harvested when the cytopathic effect rate is 70%-90% and the viable cell rate is 20%-55%. The virus fluid is then clarified by low-shear treatment to obtain a semi-finished virus product with a virus content of not less than 10^7.5 TCID50 / ml.
[0009] The freeze-drying protection system, based on the final concentration of the finished product, comprises 3%-8% trehalose, 2%-6% sucrose, 0.5%-2.0% hydrolyzed gelatin, 2%-6% skim milk powder, 0.2%-1.0% monosodium glutamate, 1%-4% hydroxyethyl starch, 0.5%-3% betaine, and a buffer salt with a pH of 7.2-7.6. The preferred volume ratio of the freeze-drying protection system to the virus semi-finished product is 1:(3-5).
[0010] The attenuated strain of bovine infectious rhinotracheitis virus is a clone that has been attenuated and purified through continuous passage in MDBK cells, and has been confirmed to be stable through viral gene identification, safety, immunogenicity, immunosuppression, and virulence reversion tests; the JSM strain is preferred.
[0011] The feed maintenance medium includes serum-free basal culture medium, L-glutamine 2-6 mmol / L, cell hydrolysate 0.3-1.2 g / L, trehalose 0.5-2.0 g / L, and poloxamer 188 0.01%-0.08%, wherein the cell hydrolysate is yeast hydrolysate, soybean hydrolysate, or a combination thereof.
[0012] The low-shear clarification includes at least one of centrifugal clarification and deep filtration; the centrifugal clarification conditions are 1000-3000×g for 5-15 minutes, the pore size of the deep filtration is not greater than 0.65 μm, and the temperature of the liquid is controlled at 2-8℃ during the clarification process.
[0013] The freeze-drying protection system is free of thiourea, or the thiourea content is less than 0.05%; the volume ratio of the freeze-drying protection system to the virus semi-finished product is 1:(3-5).
[0014] The residual moisture content of the live vaccine after freeze-drying is no higher than 3.5%, and the virus content per dose after reconstitution is no less than 10^3.5 TCID50. Furthermore, the virus content per dose remains no less than 10^3.5 TCID50 after storage at 2-8℃ for 18 months.
[0015] The present invention also provides a method for preparing the above-mentioned live vaccine, comprising the following steps: S1, preparing MDBK suspension seed cells and inoculating them into a production bioreactor for proliferation culture; S2, inoculating the MDBK suspension cells with a weakened strain of bovine infectious rhinotracheitis virus when they reach the inoculation window; S3, after inoculation, performing supplemental culture and determining the harvest endpoint according to the ratio of cytopathic effects to live cells; S4, harvesting the virus fluid and performing low-shear clarification to obtain a virus semi-finished product; S5, mixing the virus semi-finished product with a freeze-drying protection system under low-shear aseptic conditions at 2-8°C; S6, dispensing, partially capping, freeze-drying, pressing, and crimping to obtain the live vaccine.
[0016] Furthermore, in step S1, the MDBK suspension seed cells are inoculated into the production bioreactor at an inoculation density of 1.2×10^5-2.0×10^5 cells / ml, the culture temperature is 36.5-37.5℃, the stirring speed is 40-60 r / min, the pH is 7.10-7.30, and the dissolved oxygen is 45%-55%.
[0017] The inoculation window in step S2 is defined as follows: cell density of 2.8×10^6-4.5×10^6 cells / ml, cell viability of not less than 92%, pH fluctuation of not more than 0.15 and dissolved oxygen fluctuation of not more than 10% within 6 hours before inoculation.
[0018] In step S3, 6-10 hours after inoculation, a maintenance solution of 10%-35% by volume is added, and the culture continues for 18-30 hours after the addition. During the culture, the temperature is controlled at 36.5-37.5℃, the pH at 7.10-7.30, and the dissolved oxygen at 45%-55%. The addition of feed is determined by sampling and testing glucose and lactic acid.
[0019] In step S5, the stirring speed for low-shear aseptic mixing is 20-80 r / min, the mixing time is 10-30 minutes, and the foam height during mixing does not exceed 5% of the liquid height.
[0020] The freeze-drying in step S6 includes pre-freezing, primary drying, and secondary drying; the pre-freezing temperature is -45℃ to -55℃ and is maintained for 2-4 hours; the primary drying plate temperature is -35℃ to -25℃, the vacuum degree is 10-30 Pa, and it is maintained for 10-18 hours; the secondary drying plate temperature is 20℃ to 30℃ and it is maintained for 4-8 hours.
[0021] The virus semi-finished product obtained in step S4 needs to pass sterility testing, mycoplasma testing, exogenous virus testing, and virus content determination before entering the seedling process. The virus content is determined using the MDBK cell 96-well plate method, and TCID50 is calculated using the Spearman-Karber method or the Reed-Muench method.
[0022] The method is carried out in a suspension culture and low-shear mixing system, which includes an MDBK suspension seed tank, a production bioreactor, a feed maintenance solution aseptic feed line, an online pH / dissolved oxygen / temperature detection module, a glucose / lactic acid sampling and detection port, a low-shear clarification unit, a low-shear aseptic mixing tank with a temperature control jacket, a foam monitoring module, a protective solution feed unit, and a filling and freeze-drying connection line.
[0023] The present invention relates to the application of a bovine infectious rhinotracheitis virus suspension culture live vaccine in the preparation of veterinary biological products for the prevention of bovine infectious rhinotracheitis, wherein the veterinary biological products are suitable for cattle aged 3 months and older.
[0024] Compared with existing technologies, the present invention has at least the following beneficial effects: First, it expands the inoculation window from a single cell density index to a combination of cell density, cell viability, pH stability, and dissolved oxygen stability, reducing fluctuations in virus proliferation caused by differences in cell state; Second, it extends the effective virus replication window and improves the titer of the semi-finished virus product by maintaining feeding after inoculation and controlling glucose / lactic acid metabolism; Third, it determines the harvest endpoint by using both the proportion of cytopathic effects and the proportion of viable cells, avoiding batch deviations caused by harvesting at fixed times; Fourth, low-temperature, low-shear clarification and mixing reduce shear and foam damage to virus particles; Fifth, the composite freeze-drying protection system improves the virus titer retention rate during freeze-drying, reconstitution, and storage at 2-8℃ through the synergistic effects of sugar vitrification, protein colloidal protection, amino acid stabilization, polymer backbone support, and permeation protection. Detailed Implementation
[0025] Example 1: Attenuated virus strains and MDBK suspension seed cells for seedling production The attenuated strain of bovine infectious rhinotracheitis virus (BRV) for vaccine production can be obtained by attenuation and purification cloning of BRV obtained through continuous passage in MDBK cells, preferably the JSM strain. The attenuated strain was confirmed as BRV by PCR detection, sequence analysis, neutralization test, and immunofluorescence test; animal safety, immunogenicity, immunosuppression test, and virulence reversion test confirmed that it is safe for cattle and has good immunoprotective ability.
[0026] MDBK cells in good growth condition were subjected to suspension adaptation and seed expansion. Cells were inoculated into the production bioreactor at a density of 1.2×10^5-2.0×10^5 cells / ml. The culture temperature was controlled at 36.5-37.5℃, the stirring speed at 40-60 r / min, the pH at 7.10-7.30, and the dissolved oxygen at 45%-55%. After culturing for 48-72 hours, when the cell density reached 2.8×10^6-4.5×10^6 cells / ml, the cell viability was not less than 92%, and the pH fluctuation did not exceed 0.15 and the dissolved oxygen fluctuation did not exceed 10% within 6 hours before virus inoculation, the virus inoculation process commenced.
[0027] Example 2: Suspension culture maintained by feeding after inoculation Inoculate with a weakened strain of bovine infectious rhinotracheitis virus at an MOI of 0.005-0.03. After inoculation, maintain a temperature of 36.5-37.5℃, a stirring speed of 40-60 r / min, a pH of 7.10-7.30, and dissolved oxygen of 45%-55%. 6-10 hours after inoculation, add 10%-35% (v / v) of maintenance feed solution through a sterile feed line.
[0028] The feed maintenance medium includes serum-free basal culture medium, L-glutamine 2-6 mmol / L, cell hydrolysate 0.3-1.2 g / L, trehalose 0.5-2.0 g / L, and poloxamer 188 0.01%-0.08%. The cell hydrolysate is yeast hydrolysate, soybean hydrolysate, or a combination thereof. After feeding, the culture continues for 18-30 hours. During the culture period, glucose and lactate levels are monitored regularly to maintain a glucose concentration of 1.0-3.0 g / L and a lactate concentration not exceeding 3.0 g / L.
[0029] Viral fluid is harvested when the cytopathic effect rate reaches 70%-90% and the viable cell rate is 20%-55%. This harvest endpoint balances virus release and live virus stability, avoiding titer fluctuations caused by differences in cell metabolism and CPE processes in the fixed 24-36 hour harvest mode.
[0030] Example 3: Low-shear clarification and inspection of viral semi-finished products The virus culture medium obtained in Example 2 was subjected to low-shear clarification at 2-8°C. Low-shear clarification could be achieved by at least one of centrifugation and deep filtration. Centrifugation conditions were 1000-3000×g for 5-15 minutes; the pore size of the deep filter was no larger than 0.65 μm. Strong shaking and repeated pumping were avoided during the clarification process to reduce shear damage to the virus particles.
[0031] After clarification, a semi-finished viral product is obtained. This semi-finished product requires sterility testing, mycoplasma testing, exogenous virus testing, and viral load determination. Viral load determination uses the MDBK cell 96-well plate method. Samples are serially diluted 10-fold using DMEM cell culture medium containing 2% horse serum. Four dilutions (10^-2, 10^-3, 10^-4, and 10^-5) are seeded to form well-grown MDBK cell monolayers, with 0.1 ml per well for each dilution. A normal cell control is also included. The cells are incubated at 37°C in a 5% CO2 incubator and observed for 4 days. TCID50 is calculated using the Spearman-Karber method or the Reed-Muench method. A qualified semi-finished viral product must contain a viral load of at least 10^7.5 TCID50 / ml.
[0032] Example 4: Composite freeze-drying protection system and low-temperature low-shear mixture Prepare a composite lyophilization protection system. Based on the final concentration of the finished product, the composite lyophilization protection system includes 5% trehalose, 4% sucrose, 1.0% hydrolyzed gelatin, 4% skim milk powder, 0.5% monosodium glutamate, 2% hydroxyethyl starch, 1.5% betaine, and a phosphate-citrate buffer at pH 7.4. After thorough dissolution of all components, filter the solution through a 0.22 μm filter membrane for sterilization and store at 2-8℃ for later use.
[0033] Pre-cool the qualified virus semi-finished product and the composite freeze-drying protection system to 2-8℃ respectively. In a low-shear aseptic mixing tank with a temperature-controlled jacket, mix the composite freeze-drying protection system and the virus semi-finished product at a volume ratio of 1:4, with a stirring speed of 20-80 r / min and a mixing time of 10-30 minutes. Monitor the foam height during the mixing process, ensuring that the foam height does not exceed 5% of the liquid height.
[0034] The composite freeze-drying protection system is free of thiourea, or has a thiourea content of less than 0.05%. Trehalose and sucrose form a vitrification protective matrix, hydrolyzed gelatin and skim milk powder provide protein colloidal protection, hydroxyethyl starch improves the skeletal structure of the freeze-dried cake, and monosodium glutamate and betaine reduce the impact of low temperature, dehydration, and reconstitution processes on the viral envelope and related proteins.
[0035] Example 5: Dispensing and Freeze-drying After mixing, the mixture is aseptically dispensed into quantitative portions, partially capped, and then transferred to a freeze dryer. The freeze-drying process is as follows: Pre-freezing stage: the plate temperature is lowered to -45℃ to -55℃ and maintained for 2-4 hours; First drying stage: the plate temperature is controlled at -35℃ to -25℃, with a vacuum of 10-30 Pa, and maintained for 10-18 hours; Second drying stage: the plate temperature is raised to 20℃ to 30℃ and maintained for 4-8 hours. After freeze-drying, the plates are capped and sealed to obtain a live suspension culture vaccine for bovine infectious rhinotracheitis virus.
[0036] Example 6: Safety and Efficacy Inspection Safety testing was conducted using three healthy, susceptible cattle aged 3-7 months. Before vaccination, the cattle were observed for two days, with their body temperature measured daily and the average value taken as the baseline temperature. Each cattle received a 10-dose intramuscular injection of vaccine in the neck. After vaccination, their body temperature was measured daily for 14 consecutive days. Compared to before vaccination, the immunized cattle showed no significant changes in spirit or appetite, and their body temperature increased by no more than 1°C above the baseline temperature. If the body temperature exceeded the baseline temperature by 1°C but remained elevated for no more than two consecutive temperature fluctuations, the cattle were considered to have passed the safety test.
[0037] Efficacy testing can be performed using either virus content assay or immune challenge. The immune challenge method is as follows: Dilute the vaccine with sterile saline to a concentration of 1 dose / ml. Select 10 healthy, susceptible cattle aged 3-7 months. Inject 5 cattle intramuscularly into each neck, and use the other 5 as a control group. All cattle are kept in isolation under the same conditions. 28 days post-immunization, all cattle are intranasally sprayed with a virulent strain of bovine infectious rhinotracheitis virus (BVRCV). The challenge dose is 10^6.5-10^7.0 TCID50 / ml, 4.0 ml per head, 2.0 ml in each nostril. For two days prior to challenge, body temperature is measured daily and the average value is used as the baseline temperature. After challenge, clinical symptoms are observed daily, body temperature is measured regularly, and nasal swabs are collected daily for virus isolation until day 7. The efficacy test is considered successful if at least 4 control cattle develop the disease and at least 4 immunized cattle show protection.
[0038] In this application, the bovine infectious rhinotracheitis virus strain LN01 / 08 used for immune challenge evaluation has been deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 6033 and deposit date of April 20, 2012. This deposited material is used for challenge testing in efficacy evaluation and is not the sole limitation of the attenuated viral antigen used in vaccine preparation in this invention.
[0039] Example 7: Shelf life evaluation The lyophilized preparation prepared in Example 5 is stored at 2-8°C, and the appearance, resolubility, residual moisture and virus content are measured at 0, 3, 6, 12, and 18 months respectively. If the lyophilized cake is intact, no visible foreign matter is present after reconstitution, the residual moisture is not higher than 3.5%, and the virus content per dose is not less than 10^3.5 TCID50, the quality is determined to be qualified during the storage period. According to the above standards, the validity period of the live vaccine of the present invention stored at 2-8°C is no less than 18 months.
[0040] Example 8 Process Comparison Test A comparative test was carried out using the same batch of MDBK suspension seed cells and the same attenuated bovine infectious rhinotracheitis virus strain. The control process adopts a fixed virus inoculation window, no feeding maintenance after virus inoculation, harvesting at a fixed time, and a gelatin-sucrose protective system; the process of the present invention adopts the virus inoculation window described in Examples 1-5, feeding maintenance after virus inoculation, harvesting based on dual indicators of CPE / viability, low-shear clarification, and a composite lyophilization protective system. The results are shown in the table below.
[0041]
[0042] The above results show that the present invention does not simply change the conventional culture parameters, but through the combination of the virus inoculation window, feeding maintenance after virus inoculation, metabolic index control, harvest endpoint control, low-shear clarification and composite lyophilization protective system, the virus harvest titer, lyophilization survival rate and storage stability are all improved simultaneously.
[0043] The above examples show that the present invention establishes a complete live vaccine preparation scheme around the attenuated bovine infectious rhinotracheitis virus strain, MDBK suspension cell culture, feeding maintenance after virus inoculation, low-shear clarification, composite lyophilization protective system, low-temperature low-shear mixing and two-stage lyophilization, which can be used for pilot scale-up, clinical regional trials and industrial production of the bovine infectious rhinotracheitis live vaccine.
Claims
1. A live vaccine for bovine infectious rhinotracheitis virus suspension culture, characterized in that, The live vaccine is a freeze-dried preparation containing attenuated bovine infectious rhinotracheitis virus (BVRV) antigen and a freeze-drying protection system. The attenuated BVRV antigen is obtained from MDBK suspension cells through a proliferation phase and a post-inoculation maintenance phase. Specifically, before inoculation, the MDBK suspension cell density is 2.8 × 10^6–4.5 × 10^6 cells / ml, with a cell viability of not less than 92%. The attenuated BVRV strain is inoculated with an MOI of 0.005–0.
03. 6–10 hours after inoculation, a maintenance supplement of 10%–35% (v / v) is added, and the glucose concentration in the culture medium is controlled at 1.0–3.0 g / L, and the lactate concentration not exceeding 3.0 g / L. The virus fluid is harvested when the cytopathic effect rate reaches 70%–90% and the viable cell rate is 20%–55%. After low-shear clarification, the virus fluid yields a viral load of not less than 10^7.
5. The virus semi-finished product has a TCID50 / ml concentration; the freeze-drying protection system comprises, based on the final concentration of the finished product, 3%-8% trehalose, 2%-6% sucrose, 0.5%-2.0% hydrolyzed gelatin, 2%-6% skim milk powder, 0.2%-1.0% monosodium glutamate, 1%-4% hydroxyethyl starch, 0.5%-3% betaine, and a buffer salt with a pH of 7.2-7.
6.
2. The bovine infectious rhinotracheitis virus suspension culture live vaccine according to claim 1, characterized in that, The attenuated strain of bovine infectious rhinotracheitis virus is a clone that has been attenuated and purified through continuous passage in MDBK cells, and has been confirmed to be stable through viral gene identification, safety, immunogenicity, immunosuppression, and virulence reversion tests; the JSM strain is preferred.
3. The bovine infectious rhinotracheitis virus suspension culture live vaccine according to claim 1, characterized in that, The feed maintenance medium includes serum-free basal culture medium, L-glutamine 2-6 mmol / L, cell hydrolysate 0.3-1.2 g / L, trehalose 0.5-2.0 g / L, and poloxamer 188 0.01%-0.08%, wherein the cell hydrolysate is yeast hydrolysate, soybean hydrolysate, or a combination thereof.
4. The bovine infectious rhinotracheitis virus suspension culture live vaccine according to claim 1, characterized in that, The low-shear clarification includes at least one of centrifugal clarification and deep filtration; the centrifugal clarification conditions are 1000-3000×g for 5-15 minutes, the pore size of the deep filtration is not greater than 0.65 μm, and the temperature of the liquid is controlled at 2-8℃ during the clarification process.
5. The bovine infectious rhinotracheitis virus suspension culture live vaccine according to claim 1, characterized in that, The freeze-drying protection system is free of thiourea, or the thiourea content is less than 0.05%; the volume ratio of the freeze-drying protection system to the virus semi-finished product is 1:(3-5).
6. The bovine infectious rhinotracheitis virus suspension culture live vaccine according to claim 1, characterized in that, The residual moisture content of the live vaccine after freeze-drying is no higher than 3.5%, and the virus content per dose after reconstitution is no less than 10^3.5 TCID50. Furthermore, the virus content per dose remains no less than 10^3.5 TCID50 after being stored at 2-8℃ for 18 months.
7. A method for preparing a live bovine infectious rhinotracheitis virus suspension culture vaccine as described in any one of claims 1-6, characterized in that, The process includes the following steps: S1, preparing MDBK suspension seed cells and inoculating them into a production bioreactor for proliferation culture; S2, inoculating the MDBK suspension cells with a weakened strain of bovine infectious rhinotracheitis virus when they reach the inoculation window; S3, maintaining culture after inoculation with feed and determining the harvest endpoint according to the ratio of cytopathic effects to live cells; S4, harvesting the virus fluid and performing low-shear clarification to obtain a semi-finished virus product; S5, aseptically mixing the semi-finished virus product with a freeze-drying protection system at 2-8°C under low-shear conditions; S6, dispensing, partially capping, freeze-drying, stoppering, and crimping to obtain the live vaccine.
8. The preparation method according to claim 7, characterized in that, In step S1, MDBK suspension seed cells were inoculated into the production bioreactor at an inoculation density of 1.2×10^5-2.0×10^5 cells / ml, cultured at a temperature of 36.5-37.5℃, a stirring speed of 40-60 r / min, a pH of 7.10-7.30, and a dissolved oxygen level of 45%-55%.
9. The preparation method according to claim 7, characterized in that, The inoculation window mentioned in step S2 is as follows: cell density of 2.8×10^6-4.5×10^6 cells / ml, cell viability of not less than 92%, pH fluctuation of not more than 0.15 and dissolved oxygen fluctuation of not more than 10% within 6 hours before inoculation.
10. The preparation method according to claim 7, characterized in that, In step S3, 6-10 hours after inoculation, add 10%-35% of the volume of the feed maintenance solution, and continue culturing for 18-30 hours after feeding. During the culture period, control the temperature at 36.5-37.5℃, the pH at 7.10-7.30, and the dissolved oxygen at 45%-55%, and determine whether to add feed by sampling and testing glucose and lactic acid.
